Personalized medicine initiative at Gustave Roussy

Add to your list(s) Download to your calendar using vCal

• Professor Jean-Charles SORIA - Chef de Service, Professor of Medicine and Medical Oncology, Paris University XI and cancer specialist at Institut Gustave, Roussy.
• Tuesday 14 January 2014, 12:00-13:00
• CRI Lecture Theatre, Cambridge Research Institute.

If you have a question about this talk, please contact Mala Jayasundera.

Host: Dr Richard Baird

Development of genomic analysis through a personalized medicine program at Gustave Roussy

Ludovic Lacroix, Fabrice Andre, Jean-Charles Soria

The Gustave Roussy comprehensive molecular screening program is being developed to complement our hospital’s clinical trials strategy. The main molecular triage trials are shown in table 1. This whole initiative is supported by a variety of funding sources including: specific state grants, collaborative programs with biotech or pharmaceutical companies as well as philanthropic funding. The MSN (Melanoma, Small cell and Nonsmall cell lung cancer) trial was launched in 2009. It is a mono-centric molecular screening trial for tumor samples (either archived or newly collected) from patients with lung cancer and melanomas [Planchard]. The SAFIR01 trial, which was launched in 2011 for patients with metastatic breast cancer and is now closed to recruitment, required dedicated freshly frozen tumor biopsy samples. SAFIR01 was sponsored by UNICANCER , the former French Federation of Cancer Centers and funded by INCa [André ASCO ]. The upcoming SAFIR02 trials will use NGS (70 genes), CGH and treatment arms according to molecular screening results for patients with metastatic breast and non-small cell lung cancer. MOSCATO (MOlecular Screening for Cancer Treatment Optimization), was launched in 2012. It is a mono-centric molecular triage trial for early phase I candidates and combines CGH array and sequencing of a gene panel performed on fresh tumor biopsy samples [Hollebecque]. The WINTHER Trial was launched in 2013. It is an international non-randomized molecular triage study undertaken by the WIN consortium, requiring dedicated freshly frozen tumor biopsy samples and normal matched tissue used to screen for mutations, translocations and copy number variations (CNV) by NGS , completed with RNA and microRNA exploration for tumors without actionable drug targets [Kurzrock]. Data and design regarding all these trials will be presented.

References

Andre F, Thomas Denis Bachelot TD, Campone M, Arnedos M, Dieras V, Lacroix-Triki M, Lazar V, Gentien D, Cohen P, Goncalves P, Lacroix L, Chaffanet M, Dalenc F, Mathieu MC, Bieche I,Olschwang S, Wang Q, Commo F, Jimenez M. Bonnefoi HR Array CGH and DNA sequencing to personalize targeted treatment of metastatic breast cancer (MBC) patients (pts): A prospective multicentric trial (SAFIR01). ASCO MEETING ABSTRACTS Jun 17, 2013:511

Planchard D, Rahal A, Lacroix L, Ngocamus M, Auger N, Saulnier P, Dorfmuller P, Soria JC, Le Chevalier T, Besse B. Upfront genomic testing for patients with non-small cell lung cancer (NSCLC) receiving first-line platinum-based regimen: preliminary result of the MSN study. Abstract 810 European Lung Cancer Conference 2012.(Geneva).

Hollebecque A, et al. Molecular screening for cancer treatment optimization (MOSCATO 01):a prospective molecular triage trial — interim results. J. Clin. Oncol. 31, 2512 (2013).

Kurzrock, R. & Tabernero, J. WINTHER — WIN Therapeutics Clinical Trial.

http://www.winconsortium.org (WIN Consortium, 2012).

This talk is part of the Cambridge Oncology Seminar Series series.

This talk is included in these lists:

• All Talks (aka the CURE list)
• Biology
• CCC talks for website
• CRI Lecture Theatre, Cambridge Research Institute
• CRUK CI Seminars
• Cambridge Oncology Seminar Series
• Life Sciences
• Life Sciences
• ME Seminar
• MRC Cancer Unit Seminars
• PMRFPS's
• cancer
• cri
• my_list
• other talks
• se393's list
• sfm36

Note that ex-directory lists are not shown.